Abstract:Opioids are highly effective analgesics, however, their therapeutic use is limited by adverse effects that include respiratory depression, dependence, and tolerance. Inflammation has been implicated as a significant driver for the development of tolerance to opioids. Recent studies show that chronic morphine in mice results in gut microbial dysbiosis and inflammation in the colon. In the present study, we examined whether colonic inflammation results in tolerance to the antinociceptive effects of morphine. Colonic inflammation was induced in mice by intrarectal administration of 2,4,6-trinitro-benzene sulfonic acid. The development of antinociceptive tolerance was determined by warm-water tail-immersion assay in mice implanted with 25-, 50-, or 75-mg morphine pellet. Colonic inflammation significantly enhanced the rate at which tolerance developed in each cohort of chronic morphine-treated mice. At the lowest dose of morphine pellet (25 mg), antinociceptive tolerance only developed in the presence of colonic inflammation, whereas in 50- and 75-mg pelleted mice, tolerance developed faster in the inflamed animals than in the noninflamed mice. The enhanced antinociceptive tolerance was attenuated with daily administration of peripheral opioid receptor antagonist, 6 beta-N-heterocyclic-substituted naltrexamine derivative 17-cyclopropyInnethyl-3,14 beta-dihydroxy-4,5 alpha-epoxy-6 beta-[(4'pyridyl) acetamido]nnorphinan (NAP)], irrespective of colonic inflammation. Collectively, these findings show that the rate of tolerance to morphine antinociception is exaggerated in the presence of colonic inflammation, and tolerance is prevented by a peripheral mu-opioid receptor antagonist. These studies suggest a peripheral component to the development of antinociceptive tolerance to opioids. Furthermore, peripherally selective opioid antagonists may be useful adjuncts in opioid-based pain management. SIGNIFICANCE STATEMENT This study supports the notion that inflammation influences the development of antinociceptive tolerance to chronic morphine exposure. We found that, in the presence of colonic inflammation, the rate of development of tolerance to the antinociceptive effects of morphine increased. We also found that treatment with a peripheral opioid receptor antagonist prevented morphine antinociceptive tolerance. Increasing opioid intake during an inflammatory state would result in decreased analgesia and enhanced analgesic tolerance, which puts patients with inflammatory bowel diseases, inflammatory joint diseases, and sickle cell anemia at risk for heavy opioid use.

Tumor necrosis factor-α-induced protein 8-like 2 alleviates morphine antinociceptive tolerance through reduction of ROS-mediated apoptosis and MAPK/NF-κB signaling pathways

Dysregulation of Vesicular Glutamate Transporter VGluT2 Via BDNF/TrkB Pathway Contributes to Morphine Tolerance in Mice

Tiam1-mediated maladaptive plasticity underlying morphine tolerance and hyperalgesia

Involvement of neuronal TGF-β activated kinase 1 in the development of tolerance to morphine-induced antinociception in rat spinal cord.

Spinal TLR4/P2X7 Receptor-Dependent NLRP3 Inflammasome Activation Contributes to the Development of Tolerance to Morphine-Induced Antinociception

Microglial TLR4-induced TAK1 phosphorylation and NLRP3 activation mediates neuroinflammation and contributes to chronic morphine-induced antinociceptive tolerance

Suppressing HMGB1-TLR4-Mediated Neuroinflammation Alleviates Morphine Tolerance via Inhibiting AMPK-HO-1 Pathway in The Spinal Cord of Mice

Pellino1 Contributes to Morphine Tolerance by Microglia Activation Via MAPK Signaling in the Spinal Cord of Mice

Early Single Aspirin-triggered Lipoxin Blocked Morphine Anti-Nociception Tolerance Through Inhibiting NALP1 Inflammasome: Involvement of PI3k/Akt Signaling Pathway

Experimental Colitis Enhances the Rate of Antinociceptive Tolerance to Morphine Via Peripheral Opioid Receptors

Suppressing High Mobility Group Box-1 Release Alleviates Morphine Tolerance Via the Adenosine 5'-Monophosphate-activated Protein Kinase/heme Oxygenase-1 Pathway.

Toll-like Receptor 2-Melatonin Feedback Loop Regulates the Activation of Spinal NLRP3 Inflammasome in Morphine-Tolerant Rats

Inhibition of Neuronal Nitric Oxide Synthase Antagonizes Morphine Antinociceptive Tolerance by Decreasing Activation of P38 MAPK in the Spinal Microglia.

Potential Role of Spinal TRPA1 Channels in Antinociceptive Tolerance to Spinally Administered Morphine.

Role of P2X7 Receptor-Mediated IL-18/IL-18R Signaling in Morphine Tolerance: Multiple Glial-Neuronal Dialogues in the Rat Spinal Cord.

Opioid Receptor-Triggered Spinal Mtorc1 Activation Contributes to Morphine Tolerance and Hyperalgesia.

Chronic Morphine Treatment Increased the Expression of Myeloid Differentiation Primary Response Protein 88 in Rat Spinal Cord

Activation of spinal PDGFRβ in microglia promotes neuronal autophagy via p38 MAPK pathway in morphine-tolerant rats

Unraveling morphine tolerance: CCL2 induces spinal cord apoptosis via inhibition of Nrf2 signaling pathway and PGC-1α-mediated mitochondrial biogenesis

S-nitrosoglutathione reductase alleviates morphine analgesic tolerance by restricting PKCα S-nitrosation

Potential Role of CXCL10/CXCR3 Signaling in the Development of Morphine Tolerance in Periaqueductal Gray